Lundbeck

News

Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.

News

Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.

News

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

News

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.